Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07349693Phase 2Not Yet Recruiting

Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma

Role: lead

NCT03651349Phase 1Active Not Recruiting

To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers

Role: lead

NCT04381130Phase 1Not Yet Recruiting

A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer

Role: lead

NCT03234595Phase 1Completed

A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma

Role: lead

All 4 trials loaded